Efficacy of 0.5% Timolol Maleate Eye Drops for the Treatment of Facial Rosacea: A Randomized, Triple‐Blind, Placebo‐Controlled Clinical Trial
The Journal of Dermatology · 2026-06 · 53 (6) · 880-887
DOI: 10.1111/1346-8138.70249 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Dermatology, online erschienen am 27.04.2026. Verfasst von Ali Moradi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran. Hauptthemen laut MEDLINE: Rosacea, Timolol, Facial Dermatoses. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Tehran University of Medical Sciences and Health Services.
Abstract (Originalsprache)
Rosacea is a chronic skin condition with limited effective and well‐tolerated treatment options. This study investigated the efficacy of 0.5% timolol maleate eye drops in treating facial rosacea lesions. A randomized, triple‐blind, placebo‐controlled clinical trial was conducted at Razi Hospital in Tehran, involving 42 participants diagnosed with erythematotelangiectatic rosacea (ETR). Participants were randomized to receive either 0.5% timolol maleate eye drops or a placebo (distilled water) administered once daily for 4 weeks. The participants were evaluated in three visits (at baseline, after 4 weeks of treatment, and 4 weeks after stopping treatment) using a Mexameter MX18 device (for lightness and erythema), Clinician Erythema Assessment Scale (CEA), Global Flushing Severity Score (GFSS), Patient Self‐Assessment (PSA), and Visioface device (for ΔL and ΔE criteria). The primary outcome was the change in erythema severity, assessed by the Mexameter MX18 device. The timolol group significantly reduced Erythema Index ( p < 0.001) and other secondary outcomes, including CEA, PSA, and GFSS. No significant adverse effects were reported. In addition, MANOVA revealed a significant time × group interaction across outcomes, indicating that the pattern of changes over time was significantly different between the intervention and placebo groups. This study provides preliminary evidence that 0.5% timolol eye drops could be an effective and well‐tolerated treatment for facial rosacea. However, the small sample size and short follow‐up duration limited our results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
- Department of Dermatology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
- Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
ORCID-Profile: Safoura Shakoei, Shahin Hamzelou
Förderung
- Tehran University of Medical Sciences and Health Services
Zitieren
APA
Moradi, A., Shakoei, S., Hamzelou, S., Nasimi, M., Shahbazi, T., & Ayatollahi, A. (2026). Efficacy of 0.5% Timolol Maleate Eye Drops for the Treatment of Facial Rosacea: A Randomized, Triple‐Blind, Placebo‐Controlled Clinical Trial. The Journal of Dermatology, 53(6), 880-887. https://doi.org/10.1111/1346-8138.70249
Vancouver
Moradi A, Shakoei S, Hamzelou S, Nasimi M, Shahbazi T, Ayatollahi A. Efficacy of 0.5% Timolol Maleate Eye Drops for the Treatment of Facial Rosacea: A Randomized, Triple‐Blind, Placebo‐Controlled Clinical Trial. The Journal of Dermatology. 2026;53(6):880-887. doi:10.1111/1346-8138.70249
BibTeX
@article{Moradi2026,
author = {Moradi, Ali and Shakoei, Safoura and Hamzelou, Shahin and Nasimi, Maryam and Shahbazi, Taha and Ayatollahi, Azin},
title = {Efficacy of 0.5% Timolol Maleate Eye Drops for the Treatment of Facial Rosacea: A Randomized, Triple‐Blind, Placebo‐Controlled Clinical Trial},
journal = {The Journal of Dermatology},
year = {2026},
volume = {53},
number = {6},
pages = {880--887},
doi = {10.1111/1346-8138.70249}
}
EUVIMED